DYAD has raised US$10m to expand its healthcare AI across the NHS and into new markets, including secondary care and mental health services.
The Series A closed in April 2026 and will support a wider rollout of the UK company’s technology across primary care and other healthcare settings.
DYAD develops technology that turns information in unstructured clinical documents into structured data that can be incorporated into patient records and used to create tasks for other systems.
Its primary care product, BetterLetter, is used by more than 200 practices and focuses on clinical information transferred between secondary and primary care.
The company plans to use the funding to increase adoption across UK primary care while applying its AI technology to secondary care and mental health services in the NHS and internationally.
Alexander Tayler, chief executive of DYAD, said: “Some of the most important patient information is still trapped in documents that existing systems cannot properly integrate, creating an unnecessary administrative burden for healthcare teams.
“More than 200 GP surgeries are now using our technology, benefitting from a purpose built world model for clinical coding and agentic platform for healthcare administration.
“This investment will allow us to accelerate that growth and take our technology into other parts of healthcare.”
DYAD was founded six years ago by Dr Alexander Tayler and Dr Steven Hamblin.
Its GENIE system extracts information from clinical documents and converts it into structured data that can be added to patient records or used to create tasks.
In primary care, GENIE powers BetterLetter, which has processed more than five million clinical documents. Every suggestion is reviewed and approved by a member of the practice team before reaching the patient record.
GENIE uses a multi-stage process called Graph Enabled Information Extraction. Natural language processing, or NLP, identifies medical entities and aligns them with the appropriate clinical coding taxonomy, while knowledge graphs apply defined clinical rules and logic.
Large language models are used at the final stage to resolve ambiguity in the meaning of text.
The Series A was led by Sangha Capital, with participation from existing investors and a group of technology investors including Bill Tai and Carbide Ventures.
Carolina Casas Forga at Sangha Capital said: “DYAD is tackling a fundamental problem facing healthcare systems, vast amounts of valuable clinical information remain locked inside unstructured documents.
“The company has demonstrated both the strength of its technology and clear demand within primary care. We see a significant opportunity to build on that foundation and apply DYAD’s technology across the wider healthcare system.”
Following the Series A, DYAD plans to extend BetterLetter across UK general practice and pilot applications of GENIE in secondary care and mental health services.
The company also plans to expand this work more broadly across the Middle East and US.
